Compare Amgen, Inc. (AMGN) vs Spotify Technology (SPOT) Price & Performance

AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.

The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.

Spotify (SPOT) trades at $479.77, down 1.26% amid broader market strength, but maintains strong fundamental momentum with consistent earnings beats and accelerating revenue growth. The stock shows bullish technical positioning above key support levels, with analyst consensus strongly favoring buy ratings and a $617 price target representing 29% upside potential. Recent quarterly results have exceeded expectations, with Q1 2026 EPS of $4.04 beating estimates by 18%, demonstrating operational efficiency improvements.

The outlook remains positive with projected revenue growth to $17.5B in 2026 and expanding profit margins. Key risks include competitive pressure from streaming rivals and market volatility, but strong institutional support and consistent execution provide a solid foundation for continued appreciation toward analyst targets.